Cantargia strengthens executive management in preparation for late-stage clinical development
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced the strengthening of its medical team. Dr. Roger Belusa has been appointed interim Chief Medical Officer (CMO), allowing his predecessor, Dr. Ignacio Garcia-Ribas, to take up a new position within Cantargia focusing on ongoing early phase clinical studies. Dr. Belusa has over 20 years of experience in various biotech and pharma companies developing cancer therapeutics.The new appointment occurs as the clinical development of nadunolimab, Cantargia’s most advanced program, rapidly advances towards the start of late-stage